Ocean Biomedical Cash Conversion Cycle

What does Ocean Biomedical do? Ocean Biomedical, Inc. develops therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company focuses on monoclonal antibodies like Chi3l1-targeting mAbs for non-small cell lung cancer and glioblastoma multiforme. It also offers malaria-related candidates including ODA-570, a vaccine targeting PfSEA-1 and PfGARP, ODA-611, a humanized mAb therapeutic for malaria, and ODA-579, a small molecule malaria therapeutic. These products are developed from research university and medical center assets to accelerate their commercialization. The company monetizes through the development and commercialization of its product candidates. Oncology and malaria-focused therapies represent key segments, with ODA-570, ODA-611, and ODA-579 targeting specific disease areas. Research universities and medical centers are primary collaborators for asset development, providing the foundation for Ocean Biomedical's pipeline. Ocean Biomedical's revenue streams derive from the progression of its therapeutic candidates through development stages. The firm's focus on oncology and malaria therapies drives its product portfolio, with specific candidates like ODA-570, ODA-611, and ODA-579 being central to its commercial strategy. The company accelerates the development of these assets to reach market readiness. Ocean Biomedical is one of the most popular companies on Eulerpool.